Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people and are becoming more common as the ...

Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key ...

After 45 years of marriage, Mark Geddes and his wife Jill were on the verge of sleeping in separate rooms due to the ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

Some 25 years ago, a young Parkinson's disease investigator, Robert Hauser, MD, stepped to the podium at an American Academy ...

Common cough medicine revealed to slow down Parkinson's disease and dementia - A 12-month study found that Ambroxol helped ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

Inhibition of LKKR2 may rescue neurons that are dying due to a type of Parkinson’s disease that is caused by a single genetic mutation.

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.